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ABSTRACT
Objective: The purpose of this study was to prospectively test the null hypothesis that there is no
difference in the clinical effectiveness of azithromycin and erythromycin for the treatment of chla-
mydia cervicitis in pregnancy.
Methods: All antepartum obstetrical patients underwent routine screening for chlamydia cervi-
citis using a DNA probe assay (Gen-Probe Pace, San Diego, CA). Women who tested positive for
chlamydia cervicitis were prospectively randomized to receive either azithromycin 1 g orally at
enrollment, or erythromycin 500 mg orally 4 times a day for 7 days. Sexual partners were referred
to the county health department for evaluation and treatment. A test of cure was repeated in 2
weeks. Results were analyzed by chi-square analysis and Fisher’s exact test when indicated.
Results: One hundred forty women tested positive for chlamydia cervicitis and agreed to ran-
domization. There were 4 (6.2%) treatment failures in the azithromycin group and 18 (27.7%) in
the erythromycin group (P 0.005). Gastrointestinal side effects were reported by 42 (65.5%) of the
women taking erythromycin, but only 12 (19.4%) of those taking azithromycin (P < 0.002). Gas-
trointestinal side effects and resultant noncompliance were significantly related to treatment failure
with erythromycin.
Conclusions: The findings of this study support the conclusion that a single dose of azithromycin
is a significantly more effective and better tolerated treatment regimen for chlamydia cervicitis in
pregnancy than erythromycin which is currently recommended. Infect. Dis. Obstet. Gynecol. 4:
333-337, 1996. (C) 1997 Wiley-Liss, Inc.
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creening for Ch/amydia trachomatis cervicitis is
currently recommended at both the initial pre-
natal visit and again in the third trimester due to its
high prevalence and potential for both maternal
and neonatal infectious morbidity. Doxycycline or
tetracycline are the treatments of choice for chla-
mydial infection in the nonpregnant woman, how-
ever, erythromycin is recommended by the Cen-
ters for Disease Control (CDC) during pregnancy.
Due to its frequent dosing scheduling (4 times a
day for 7 days) and a high rate of gastrointestinal
side effects, compliance with erythromycin
presents a major problem in treating chlamydia
during pregnancy. Azithromycin, an azilide antibi-
otic, has been shown to have therapeutic equiva-
lency with doxycycline in the nonpregnant popu-
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lation, z Azithromycin has several potential advan-
tages that affect compliance including a single-dose
regimen and a much lower rate of side effects.
The purpose of this study was to determine the
effectiveness of a single dose of azithromycin in
comparison with the standard 7-day erythromycin
treatment regimen for chlamydia cervicitis during
pregnancy.
SUBJECTS AND METHODS
The reported study is a prospective randomized
trial of azithromycin vs. erythromycin for the treat-
ment of chlamydia cervicitis in pregnancy. The re-
search protocol was approved by the Institutional
Review Board of the Medical University of South
Carolina.
Routine screening for chlamydia cervicitis and
gonorrhea was performed on all antepartum pa-
tients at their first prenatal visit and again in the
third trimester (32-36 weeks gestation). All preg-
nant women over the age of 15 years who tested
positive for Chlamydia trachomatis by DNA hybrid-
ization (Gen-Probe Pace, San Diego, CA) from a
cervical swab specimen were eligible for enroll-
ment. The only exclusion to enrollment was an
allergy to or intolerance of either azithromycin or
erythromycin.
Informed consent was obtained from all eligible
patients who agreed to participate in this study.
Patients were then randomized, using a preestab-
lished random number table, to one of the two
treatment regimens: enteric-coated erythromycin
base 500 mg tablets, administered orally before
meals 4 times each day for 7 days, or azithromycin
250 mg tablets, 4 tablets taken orally at enrollment.
Patients were provided with the assigned antibiot-
ics as part of the study design.
No attempt was made to blind the study. All
sexual partners were referred to the appropriate
county health department for treatment. Patients
were scheduled to return for repeat cervical culture
(test of cure) using the DNA hybridization tech-
nique 2 weeks following initiation of antibiotic
therapy. Questionnaires regarding demographic
data, obstetrical history, sexual history, history of
sexually transmitted diseases (STDs), compliance
with the treatment regimen, side effects, interval
sexual intercourse, and whether or not the sexual
partner received treatment were given to the pa-
tient both before and after treatment. These ques-
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TABLE I. Demographics of the study patients with
chlamydia cervicitis (N 130)
Azithromycin Erythromycin
group group
Demographics (n 65) (n 65) P
Age (years) 21.6 22. 0.63
Black race (%) 82. 80.6 0.83
Gravidity 2.4 2.7 0.17
Parity 1.0 I. 0.46
Gestational age
at enrollment (weeks) 20.4 28.6 0.002
tionnaires were used to analyze contributing factors
which might have influenced treatment outcome.
Results from the test of cure were compared
between the two treatment groups using chi-square
analysis and Fishcr’s exact test when indicated.
The sample size of 65 patients in each treatment
group was selected in order to detect a 15% differ-
ence in efficacy with a 95% confidence interval and
a power of 80%. A cure rate of 80% was estimated
for the group given erythromycin.3-s
RESULTS
One hundred forty obstetrical patients were en-
rolled following a positive DNA hybridization test
for chlamydia cervicitis at the Medical University
of South Carolina between April 1993 and July
1994. Ten patients were lost to follow-up and a test
of cure was not obtained: 7 patients in the eryth-
romycin group and 3 in the azithromycin group.
Sixty-two of the 65 patients in the azithromycin
group completed their post-treatment question-
naires, while 64 of the 65 patients in the erythro-
mycin group completed the same form.
The two treatment groups were similar with re-
spect to age, race, gravidity, and parity (Table 1).
Unexpectedly, a difference of 8.2 weeks in gesta-
tional age was found between the two treatment
groups (erythromycin 28.6 weeks; azithromycin
20.4 weeks; P 0.002).
Perinatal outcome was not different between
the two groups. The mean gestational ages at birth
were 38.8 +_ 1.6 and 38.0 _+ 2.0 weeks for the azithro-
mycin and erythromycin groups, respectively. In
the azithromycin group, there were 6 (9.2%) pre-
term deliveries (<37 weeks) of which 3 were due to
preterm premature rupture of the membranes
(PROM). In the erythromycin group, there were 8
(12.3%) preterm deliveries of which 5 were due to
preterm PROM. There were no stillbirths, neona-
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TABLE 2. Efficacy of treatment based on a follow-up DNA hybridization test 2 weeks after treatment and the
completion of the follow-up patient questionnaire
Azithromycin Erythromycin
(n 62) (n 64) P Odds ratio
Treatment failure 4 (6.2%) 18 (27.7%) 0.005 0.17 (0.05-0.59)
Compliance 62 (100%) 38 (59.4%) 0.001 N/A
Side effects 12 (19.4%) 42 (65.6%) 0.002 0.13 (0.05-0.30)
Partner treated 37 (59.7%) 33 (51.6%) 0.60 1.4 (0.65-3.00)
Interval intercourse 23 (37. I%) 16 (25.0%) 0.16 1.8 (0.79-4.18)
aNinety-five percent confidence intervals in parentheses.
bTreatment failure rates based on all 65 patients in each group who had the follow-up DNA hybridization test.
tal deaths, or serious anomalies in either group.
One child in the azithromycin group had polydac-
tyly and one in the erythromycin group had a small
ventricular septal defect that has not required sur-
gical repair.
Treatment failure was detected 2 weeks after
the prescribed treatment regimen in 18 (27.7%) pa-
tients in the erythromycin group but only 4 (6.2%)
patients in the azithromycin group (P 0.005)
(Table 2). There was also a significant increase in
the frequency of side effects reported by the eryth-
romycin group and a significant decrease in the
degree of compliance (Table 2). No significant dif-
ferences were reported in the number of active
sexual partners treated by the differing health de-
partments or in the frequency of reported sexual
intercourse prior to the test of cure between the
two groups (Table 2).
Of the 62 women completing their post-
treatment questionnaire in the azithromycin group,
12 (19.4%) reported side effects. Seven (11.3%) ex-
perienced nausea and 4 (6.5%) had emesis. One
other patient reported pruritus. Side effects were
reported by 42 (65.6%) of the 64 women complet-
ing their questionnaire after erythromycin treat-
ment. Thirteen (20.3%) reported nausea, 23
(35.9%) emesis, 3 (4.7%) diarrhea, (1.6%) cramp-
ing, and each reported dizziness and pruritus.
Patients who had significant side effects with
erythromycin were noncompliant 55% of the time
compared to only 16.7% (P 0.002) for patients
who did not report any major side effects. The
impact of compliance on the cure rate was dramatic
(Fig. 1). For those patients receiving crythromycin,
the cure rate was much lower (51.9%) for those
women who self-reported noncompliance com-
pared to those who reported compliance (86.8%; P
< 0.01). When only those patients in the erythro-
mycin group who reported good compliance are
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Fig. I. Comparison of cure rates between the azithromy-
cin group (N 65) with observed 100% compliance and
those patients receiving erythromycin who self-reported
either compliance (N 38) or noncompliance (N 27) with
the treatment regimen.
considered, successful treatment was not signifi-
cantly different between the groups (erythromycin
compliant 86.8%; azithromycin 93.8%).
DISCUSSION
C. trachomatis is a significant cause of both obstet-
rical and neonatal morbidity. Of those infants ex-
posed to infected cervical secretions during deliv-
ery, up to 40% develop chlamydial conjunctivitis
and 10-20% develop pneumonia.
6 C. trachomatis
has also been associated with postpartum and
postabortal endometritis,s,7
Erythromycin is the currently recommended an-
tibiotic of choice for chlamydia cervicitis in preg-
nancy. Erythromycin has been reported to have
76-100% efficacy in the treatment of chlamydial
infections in nonpregnant populations.3,4 An 83.3%
cure rate was reported in a large, randomized treat-
ment trial of chlamydia cervicitis in pregnancy,s
However, in the current study, the recommended
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regimen of erythromycin base, 500 mg taken orally
before meals 4 times daily, caused a significant
number of patients to experience untoward gastro-
intestinal side effects, such as nausea, vomiting,
gastritis, and diarrhea. These side effects, along
with a difficult dosing regimen, contributed to a
high rate of noncompliance with this antibiotic and
a significantly higher failure rate.
A number of other antibiotic regimens have
been studied in nonpregnant women for the treat-
ment of chlamydia cervicitis, including tetracy-
cline, doxycycline, sulfisoxazolc, and several of the
quinolones. However, these drugs are generally
contraindicated in pregnancy. Clindamycin and
amoxicillin have both been investigated during
pregnancy and may be as efficacious as erythromy-
cin in the treatment of chlamydia cervicitis, s,8
While both of these antibiotics have fewer side ef-
fects than erythromycin, they also have a multidose
daily treatment regimen that affects compliance.
Azithromycin is the prototype of a new class of
antibiotics, the azilides. They have been shown to
be as efficacious as doxycycline for the treatment of
chlamydia cervicitis in nonpregnant women, z This
was demonstrated with a single-star g dose of
azithromycin compared to a standard 7-day doxy-
cycline regimen of 100 mg twice a day. On recul-
ture, 98% of women in both groups were free of
disease, z In a single small investigation, the effi-
cacy of azithromycin and erythromycin was com-
pared in 30 pregnant women with cervical chla-
mydial infection.9 Despite a high rate of gastroin-
testinal side effects in the subjects receiving
erythromycin, there was no difference in efficacy
between the two groups. Unfortunately, the small
sample size prevented the investigation from hav-
ing adequate power to discriminate between the
two treatment regimens.
Azithromycin is closely related to erythromycin,
although its pharmacokinetics differ greatly.
Azithromycin differs from erythromycin due to an
insertion of a methyl-substituted nitrogen atom
into the aglycone ring. This insertion allows for
rapid intracellular transfer which potentially makes
it more effective against chlamydia, which is an
obligate intracellular parasite. Erythromycin has
less effective intracellular penetrance and therefore
relies more heavily on eradication of the organism
during the transient extracellular portion of chla-
mydia’s 48-72-h life cycle. Because of these phar-
macokinetics, erythromycin will only obtain com-
parable cure rates when it can achieve adequate se-
rum levels for a more prolonged treatment course.
Although the available data arc limited, there
are no reported or anticipated differences in fetal
risk between azithromycin and erythromycin. Both
drugs carry a Pregnancy Category B designation
with no known effects on pregnancy or the devel-
oping fetus.1 It is noted that the current study has
minimal power to detect any differences in perina-
tal outcome between the two drug regimens.
The results of this study demonstrate that a
single-stat dose of azithromycin is more effective
than a 7-day course of erythromycin for the treat-
ment of chlamydia cervicitis in pregnancy. In fact,
patients in the erythromycin treatment group had
more than a four-fold increased risk of persistent
chlamydia cervicitis at the 2-week follow-up testing
compared to patients in the azithromycin group.
Treatment failures were seen in both antibiotic
groups. Possible explanations include reinfection
by an untreated partner, organism resistance to the
drug, or incomplete penetration of the drug at the
site of infection. It was anticipated that these fac-
tors would pose equivalent risks in both treatment
groups. Indeed, no significant differences were
seen in either the partner treatment rates or the
reported rates of interim intercourse between the
two groups.
Eligible patients were assigned to a treatment
regimen based on a preestablished random number
table as they were enrolled in the study without
consideration of age, race, parity, or gestational age.
No inherent bias can be identified in the study
design. We cannot explain the difference in the
mean gestational age between the two study
groups except as an unlikely chance event. Al-
though unlikely, it cannot be excluded that the
difference in gestational age between the two
groups could have affected the efficacy of one or
the other treatment regimen. A greater propensity
for gastrointestinal side effects might be expected
at earlier gestational ages, but that was not the case
in this study. The women receiving azithromycin
did so at a significantly earlier gestational age, yet
had fewer gastrointestinal side effects. Erythromy-
cin, theoretically, could have been less effective at
28 weeks due to a larger blood volume of distribu-
tion compared to 20 weeks; however, the dosage of
erythromycin used was standard for any point dur-
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ing pregnancy. Reinfection rates would also be ex-
pected to be lower at 28 weeks due to a reduced
frequency of sexual intercourse with advancing
gestation. However, while unlikely, it is not incon-
ceivable that the difference in gestational age be-
tween the two study groups could have affected
the outcomes of interest.
Treatment of chlamydia cervicitis with azithro-
mycin is more expensive than treatment with
erythromycin. However, the costs of retreatment
and maternal and neonatal sequelae .from persis-
tent C. trachomatis infection arc significant and help
justify the additional expense of azithromycin.
Based on its enhanced efficacy and compliance is-
sues, we suggest that azithromycin be considered
the treatment of choice for chlamydia cervicitis in
pregnancy.
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